Gabriella Sozzi
Overview
Explore the profile of Gabriella Sozzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
4728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boeri M, Sabia F, Ledda R, Balbi M, Suatoni P, Segale M, et al.
Lancet Reg Health Eur
. 2024 Sep;
46:101070.
PMID: 39319217
Background: The proper management of suspicious radiologic findings is crucial to optimize the effectiveness of low-dose computed tomography (LDCT) lung cancer screening trials. In the BioMILD study, we evaluated the...
2.
Parodi M, Centonze G, Murianni F, Orecchia P, Andriani F, Roato I, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38458638
Background: Epithelial to mesenchymal transition (EMT) endows cancer cells with pro-metastatic properties, which appear most effective when cells enter an intermediate hybrid (H) state, characterized by integrated mesenchymal (M) and...
3.
Boeri M, Signoroni S, Ciniselli C, Gariboldi M, Zanutto S, Rausa E, et al.
Cancer Gene Ther
. 2024 Feb;
31(6):842-850.
PMID: 38332046
Lynch syndrome (LS) is an inherited condition characterized by an increased risk of developing cancer, in particular colorectal cancer (CRC). Microsatellite instability (MSI) is the main feature of (pre)cancerous lesions...
4.
Ndembe G, Intini I, Moro M, Grasselli C, Panfili A, Panini N, et al.
J Exp Clin Cancer Res
. 2024 Jan;
43(1):6.
PMID: 38163906
Background: About 10% of NSCLCs are mutated in KRAS and impaired in STK11/LKB1, a genetic background associated with poor prognosis, caused by an increase in metastatic burden and resistance to...
5.
Sozzi G, Pastorino U
J Thorac Oncol
. 2023 Oct;
18(11):1428-1430.
PMID: 37879762
No abstract available.
6.
Petraroia I, Ghidotti P, Bertolini G, Pontis F, Roz L, Balsamo M, et al.
Cell Death Dis
. 2023 Oct;
14(10):681.
PMID: 37838700
Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer development. COPD induces activation of hypoxia-induced signaling, causing remodeling of surrounding microenvironmental cells also modulating the release and...
7.
Ruggirello M, Valsecchi C, Ledda R, Sabia F, Vigorito R, Sozzi G, et al.
Lung Cancer
. 2023 Oct;
185:107387.
PMID: 37801898
Background: This study explored female and male overall mortality and lung cancer (LC) survival in two LC screening (LCS) populations, focusing on the predictive value of coronary artery calcification (CAC)...
8.
Blandino G, Dinami R, Marcia M, Anastasiadou E, Ryan B, Palcau A, et al.
J Exp Clin Cancer Res
. 2023 Jul;
42(1):189.
PMID: 37507791
The 5th Workshop IRE on Translational Oncology was held in Rome (Italy) on 27-28 March at the IRCCS Regina Elena National Cancer Institute. This meeting entitled "The New World of...
9.
Ferrarini F, Zulato E, Moro M, Del Bianco P, Borzi C, Esposito G, et al.
Front Oncol
. 2023 Mar;
13:1070505.
PMID: 36925926
Introduction: Genetically characterized patient-derived tumor xenografts (PDX) are a valuable resource to understand the biological complexity of cancer and to investigate new therapeutic approaches. Previous studies, however, lack information about...
10.
Indino S, Borzi C, Moscheni C, Sartori P, De Cecco L, Bernardo G, et al.
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555441
Hyperprogressive disease (HPD), an aggressive acceleration of tumor growth, was observed in a group of cancer patients treated with anti-PD1/PDL1 antibodies. The presence of a peculiar macrophage subset in the...